Page 13 of the presentation:
"Monepantel displays a superior safety, tolerability and preliminary efficacy profile to the leading FDA
approved drug Relyvrio®"
This is probably as good as it gets at phase 1. Better then I thought especially with the life expectancy.
Key takeaway being 13.5-56.5 months additional life expectancy compared to Relyvrio 8-9 months?
Seminar about to start.
Ann: Presentation - Phase 1 Top-Line Results, page-7
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 18.0¢ | $28.08K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 272008 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 94021 | 3 |
View Market Depth
| Last trade - 10.06am 21/05/2024 (20 minute delay) ? |
| PAA (ASX) Chart |